GlassScriptPhysician profile
Ishmam Ibtida
NPI 1396309084
$2,570.48
in general payments reported to CMS, 2019-2025
18 companies · $837 in 2025
The $837 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $1,596 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.88 |
| Education | $268.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,034.31 | 2024-2025 | Cardiomems, Ensite, Optis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.51 | 2023-2024 | Jardiance |
| Amgen INC. | $247.07 | 2024 | Repatha |
| Janssen Scientific Affairs, LLC | $200.82 | 2024 | Xarelto |
| Chiesi USA, INC. | $153.72 | 2023-2025 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $125.39 | 2025 | Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $124.77 | 2024 | Winrevair |
| Pfizer INC. | $103.56 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $86.02 | 2025 | |
| Medtronic, INC. | $51.42 | 2024 | Cobalt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $27.08 | 2024 | |
| Terumo Medical Corporation | $25.65 | 2025 | Metacross Otw, Progreat, Glidewire |
| Abiomed | $20.51 | 2025 | |
| Esperion Therapeutics, INC. | $16.29 | 2023 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.88 | 2025 | Tryvio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2025 | Eliquis |
| Philips North America LLC | $14.15 | 2025 | Lm Accessories |
| Novo Nordisk INC | $14.02 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishmam Ibtida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.